Regeneron Pharmaceuticals

Yahoo Finance • 2 days ago

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type... Full story

Yahoo Finance • 2 days ago

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly re... Full story

Yahoo Finance • 2 days ago

Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique

Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par une étude de phase... Full story

Yahoo Finance • 5 days ago

1 No-Brainer Biotech Stock To Buy Today and Never Sell

When you think of biotech companies, you may think of exciting young players that haven't yet commercialized a product. Those exist and, in some cases, make excellent investments. But you also might consider picking up a biotech player tha... Full story

Yahoo Finance • 7 days ago

Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price ta... Full story

Yahoo Finance • 7 days ago

Regeneron Pharma Says FDA Accepts Garetosmab BLA For Priority Review For Adults With FOP

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for garetosmab for the treatment of adults with... Full story

Yahoo Finance • 7 days ago

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and o... Full story

Yahoo Finance • 9 days ago

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapie... Full story

Yahoo Finance • 9 days ago

Ocular drops after late-stage trial data for wet AMD therapy

[An arrow pointing downwards on top of a pile of US dollar bills.] Ocular Therapeutix (OCUL [https://seekingalpha.com/symbol/OCUL]) lost ~22% in the premarket on Tuesday after the company released data from a late-stage trial evaluating A... Full story

Yahoo Finance • 13 days ago

Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price... Full story

Yahoo Finance • 15 days ago

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m.... Full story

Yahoo Finance • 16 days ago

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab)data highlight... Full story

Yahoo Finance • 18 days ago

​Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook

Sanofi (NASDAQ:SNY) is one of the best 52-week low blue-chip stocks to buy right now. On January 29, Sanofi SA (NASDAQ:SNY) reiterated plans to conduct a €1 billion share buyback in 2026. The buyback push comes as the company delivered a s... Full story

Yahoo Finance • 22 days ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.'s share was trad... Full story

Yahoo Finance • 2 months ago

Stocks Fall Slightly in Thin Holiday Trade

The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -0.14%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.20%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.25%.  March E-mini S&P futures (ESH26) fell -0.14%, and M... Full story

Yahoo Finance • 2 months ago

Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX) (SPY) today is down -0.12%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.25%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.11%.  March E-mini S&P futures (ESH26) are down -0.11%, and March E-mini N... Full story

Yahoo Finance • 2 months ago

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and im... Full story

Yahoo Finance • 2 months ago

Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique

Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants démontrant que le Dupixent a considérablement réduit l... Full story

Yahoo Finance • 2 months ago

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first and only biologic med... Full story

Yahoo Finance • 2 months ago

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 20... Full story